Publications · April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

First-in-Human Healthy Volunteer Trial

In Arteriosclerosis, Thrombosis, and Vascular Biology; 2019; Vol 39 Issue 5; 956-964. Published on April 25th, 2019

Download full article (PDF)

Authors

Christine Voors-Pette, Kristell Lebozec, Peter Dogterom, Laurie Jullien, Philippe Billiald, Pauline Ferlan, Lionel Renaud, Olivier Favre-Bulle, Gilles Avenard, Matthias Machacek, Yannick Plétan, Martine Jandrot-Perrus.

Abstract

Objective—ACT017 is a novel, first in class, therapeutic antibody to platelet GPVI (glycoprotein VI) with potent and selective antiplatelet effects. This first-in-human, randomized, placebo-controlled phase 1 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACT017 in healthy subjects.

Conclusions—The novel antiplatelet agent ACT017 has consistent pharmacokinetic/pharmacodynamic properties and favorable safety and tolerability profiles warranting further clinical development.

Read next in 'Publications'